

## Special Issue

# Therapeutic Antibodies against Infectious Diseases

### Message from the Guest Editor

Therapeutic antibodies have revolutionized modern medicines, notably the treatment of cancer, autoimmune disorders and infectious diseases. Despite their clinically proven efficacy, the use of therapeutic antibody is mainly limited to richer countries. Indeed, an estimated 80% of therapeutic antibodies are administered in North America and Europe alone. The prohibitive costs of therapeutic antibodies and to a lower extent the need for intravenous administration have been hurdles to their wide-spread use. Various solutions are currently in pre-clinical phases of development. Notably, antibody gene therapy in which the nucleotide sequence of therapeutic antibodies, rather than proteins, are administered could help reduce the cost of antibody therapy. Sub-cutaneous formulation have also been developed to facilitate the administration of therapeutic antibodies. This issue will focus on research encompassing novel therapeutic antibodies against infectious diseases. Submissions, on innovative work that could facilitate the broader use of therapeutic antibody globally, are also encouraged.

### Guest Editor

Dr. Hugues Fausther-Bovendo

Department of Immunology and Microbiology, The Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA

### Deadline for manuscript submissions

closed (30 September 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/160218](https://mdpi.com/si/160218)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).